Neffy now available nationwide without prescription

Canada has reclassified the epinephrine nasal spray 'neffy' as a Schedule II product, allowing it to be sold without a prescription. This provides a needle-free alternative for individuals at risk of anaphylaxis, addressing barriers associated with traditional injectable devices.
Why it matters
This change significantly improves accessibility for millions of Canadians with severe allergies by removing the requirement for a doctor's visit to obtain life-saving emergency treatment.
Canadians with severe allergies will now have greater access to what experts have called a game-changing treatment that delivers epinephrine without the use of a needle.
ALK-Abelló Pharmaceuticals Inc. Canada (ALK Canada) announced on Monday that its epinephrine nasal spray called “neffy” is now classified as a Schedule II product in Canada, meaning it’s available without a prescription across the country.
“Access to epinephrine is critical for the estimated 2.5 million Canadians affected by severe allergies that put them at risk of anaphylaxis,” the company said in a press release .
For years, Canadians at risk of anaphylaxis from allergies to foods like peanuts or shellfish have relied on single-use injectable devices, known commonly by the brand name EpiPen, which must be jabbed into the thigh.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in